![](https://www.infextx.com/wp-content/uploads/map.gif)
We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Breaking News
Infex strengthens its senior leadership team
May 20, 2024
Appointment of Director of Clinical Programmes and changes to senior management team
Infex webinar – broader pipeline and growth strategy
May 14, 2024
On 9th May 2024, Infex Therapeutics held a live webinar, to update on the company's broader pipeline and growth strategy.
Infex welcomes the UK government’s new five-year plan to combat antimicrobial resistance
May 8, 2024
Infex Therapeutics, a leading anti-infectives specialist, welcomes the UK government’s new five-year national action plan to help combat antimicrobial resistance (AMR) and protect people and animals…
Latest News
Infex strengthens its senior leadership team
May 20, 2024
Appointment of Director of Clinical Programmes and changes to senior management team
Infex webinar – broader pipeline and growth strategy
May 14, 2024
On 9th May 2024, Infex Therapeutics held a live webinar, to update on the company's…
Infex welcomes the UK government’s new five-year plan to combat antimicrobial resistance
May 8, 2024
Infex Therapeutics, a leading anti-infectives specialist, welcomes the UK government’s…
Infex to present webinar on broader pipeline and growth strategy
April 18, 2024
Infex Therapeutics, a leading anti-infectives specialist, announces it will be holding a…
Webinar on Infex’s Phase II lead respiratory drug, RESP-X
February 6, 2024
On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with our lead…
Infex to present webinar on lead Phase II respiratory drug RESP-X
January 16, 2024
RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the frequency of…
RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients
November 2, 2023
No adverse events reported across all cohorts
Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
August 22, 2023
RESP-X continues to exhibit strong safety and tolerability profile
Sign up complete!
×Thank you for signing up to The AMR Centre’s mailing list which will ensure a timely flow of information and news.